Caxton Associates LP bought a new stake in shares of INC Research Holdings, Inc. (NASDAQ:INCR) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,100 shares of the company’s stock, valued at approximately $298,000.

Other large investors have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of INC Research Holdings by 14.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,765 shares of the company’s stock valued at $103,000 after purchasing an additional 228 shares in the last quarter. Pacad Investment Ltd. purchased a new position in shares of INC Research Holdings during the 2nd quarter valued at approximately $123,000. Riverhead Capital Management LLC purchased a new position in shares of INC Research Holdings during the 2nd quarter valued at approximately $128,000. Victory Capital Management Inc. increased its holdings in shares of INC Research Holdings by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 2,377 shares of the company’s stock valued at $139,000 after purchasing an additional 356 shares in the last quarter. Finally, Invictus RG purchased a new position in shares of INC Research Holdings during the 1st quarter valued at approximately $115,000. 54.56% of the stock is owned by hedge funds and other institutional investors.

Shares of INC Research Holdings, Inc. (NASDAQ INCR) opened at 54.75 on Friday. The company has a 50-day moving average of $54.68 and a 200-day moving average of $53.63. The firm has a market cap of $2.97 billion, a PE ratio of 33.55 and a beta of 1.34. INC Research Holdings, Inc. has a 1-year low of $40.65 and a 1-year high of $61.10.

INC Research Holdings (NASDAQ:INCR) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.64 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. INC Research Holdings had a return on equity of 40.69% and a net margin of 5.69%. The business had revenue of $258.10 million during the quarter, compared to analysts’ expectations of $256.76 million. During the same quarter in the prior year, the business earned $0.61 earnings per share. The company’s quarterly revenue was down .3% compared to the same quarter last year. Analysts predict that INC Research Holdings, Inc. will post $2.62 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/14/caxton-associates-lp-takes-position-in-inc-research-holdings-inc-incr.html.

In other INC Research Holdings news, CFO Gregory S. Rush sold 41,420 shares of the stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $58.26, for a total value of $2,413,129.20. Following the completion of the transaction, the chief financial officer now owns 42,793 shares in the company, valued at $2,493,120.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Alistair Macdonald sold 8,828 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $55.65, for a total value of $491,278.20. Following the completion of the transaction, the chief executive officer now owns 110,629 shares of the company’s stock, valued at approximately $6,156,503.85. The disclosure for this sale can be found here. Insiders have sold 198,321 shares of company stock valued at $11,550,792 in the last 90 days. Company insiders own 0.24% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Credit Suisse Group assumed coverage on shares of INC Research Holdings in a report on Wednesday. They set an “outperform” rating and a $68.00 target price for the company. Jefferies Group LLC raised shares of INC Research Holdings from a “hold” rating to a “buy” rating and lifted their target price for the company from $62.50 to $69.00 in a report on Monday, October 9th. Robert W. Baird reaffirmed a “buy” rating and set a $67.00 target price on shares of INC Research Holdings in a report on Monday, October 9th. Zacks Investment Research lowered shares of INC Research Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Mizuho assumed coverage on shares of INC Research Holdings in a report on Thursday, September 21st. They set a “neutral” rating and a $57.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $64.22.

About INC Research Holdings

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Institutional Ownership by Quarter for INC Research Holdings (NASDAQ:INCR)

Receive News & Stock Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related stocks with our FREE daily email newsletter.